Rare pulmonary side effects of brigatinib often resolve without treatment discontinuation

May 21, 2019

Brigatinib is a next-generation ALK inhibitor that earned FDA approval in 2017 as a second-line therapy after treatment with crizotinib for ALK-positive non-small cell lung cancer. Recently, clinical trial results published in the New England Journal of Medicine and presented at the 2018 World Conference on Lung Cancer show its promise as a first-line therapy. However, while brigatinib is commonly well-tolerated, in about 3% of cases, patients report experiencing shortness of breath within hours of starting treatment. With severe symptoms or if even mild symptoms occur after stopping and then restarting the drug, the manufacturer's guidelines suggest permanently ceasing use. Now a study by researchers at Columbia University, University of California San Diego, and University of Colorado Cancer Center, published this morning in the Journal of Thoracic Oncology, offers insight into the seriousness and duration of these symptoms, and suggests an alternative treatment strategy that could allow more patients to benefit from this drug.

"Although pneumonitis - inflammation in the lungs - has been reported as a rare side-effect with many targeted anti-cancer therapies usually after several weeks of therapy, the shortness of breath that patients have experienced with brigatinib appears unique," says D. Ross Camidge, MD, PhD, Joyce Zeff Chair in Lung Cancer Research at CU Cancer Center. "Firstly, when it happens, it happens within hours to days of starting the drug. Secondly and most importantly, this study shows that this side effect can also disappear within days despite continued exposure to the drug."

Case studies illustrated the four following strategies and outcomes, three of which were successful:"Our study shows that with appropriate supportive care many patients who experience this rare side effect can come to tolerate brigatinib very rapidly and continue on the drug as if nothing happened," Camidge says. "However, if the symptoms are severe enough that the initial decision is made to hold the drug, the study also gives the successful example of restarting at a fraction of the usual starting dose and then increasing every few days, reaching full dose only a little later than normal as a way to 'sneak up' on safely building tolerance."

Dr. Camidge points out that if patients in the clinical trials were fitter than the overall lung cancer population, it is only after a drug's approval, when prescribing oncologists may be giving the drug to a wider range of patients that the frequency of side effects may increase.

"Maybe the physiology behind these events happens to everybody, but some patients are just closer to the respiratory edge and manifest symptoms in that first week before they tolerize," Camidge says. "Outside of a trial, some patients may be being treated who are closer to that edge. If we can identify patients with poorer baseline respiratory function upfront, maybe just using old-fashioned clinical skills, it could be an indication in such patients that we should start brigatinib at a lower dose, say 30mg, then rapidly dose-escalate every few days as the safest way to get to the full and most effective dose. For fit patients, the standard dosing regimen should be just fine, however."

The study highlights the contributions of prescribing physicians in refining the use of new anti-cancer therapies.

"It's one thing to have a drug that we know works well against cancer," says Camidge. "But only by combining the data of a drug's effectiveness with clinical observations, in this case from outstanding colleagues around the United States, can we ensure that we are optimizing the use of these drugs with real patients who need them."

University of Colorado Anschutz Medical Campus

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.